Login
Quoin Pharmaceuticals Ltd. logo

Quoin Pharmaceuticals Ltd.

quoinpharma.com

What Do They Do?

Develops topical drug candidates for rare and orphan diseases, including skin treatments for people with Netherton Syndrome and Peeling Skin Syndrome.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

The company is developing treatments for patients with rare and orphan diseases, and plans to sell directly in the U.S., Europe and Japan while using distribution partners in other territories.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −23% (Loss)
vs −$3.9M in Q3 FY2025
  • Nov 5, 2026 Reported positive interim results from the Netherton Syndrome study The company reported positive interim data and said it expects to complete recruitment by year-end and report topline results in the second quarter of 2027.
  • Oct 14, 2026 Received European orphan drug designation for QRX003 in Peeling Skin Syndrome The company said it intends to start the first formal clinical study for Peeling Skin Syndrome before year-end.
  • Aug 27, 2026 Agreed to a private placement of up to $50.0 million The company said net proceeds, assuming cash exercise of all accompanying warrants, are expected to fund operations into the second half of 2029.

Pipeline focus The older report also described a candidate for a blistering skin disease and a research-stage candidate for Netherton Syndrome. The latest report focuses on a topical lotion for Netherton and Peeling Skin syndromes and topical rapamycin formulations.

Who Do They Compete With?

Competes with LifeMax Laboratories, Sixera Pharmaceuticals, ResVita Bio, BioCryst, and Azitra

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support